Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy and chronic hepatitis B virus infection. The company was founded in 1995 and is headquartered in Hayward, California.
IPO Year: 2015
Exchange: NASDAQ
Website: benitec.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/12/2024 | $17.00 | Buy | Guggenheim |
7/22/2024 | $13.00 | Outperform | Leerink Partners |
6/13/2024 | $30.00 | Overweight | Piper Sandler |
2/17/2022 | $10.00 | Buy | HC Wainwright & Co. |
-The post-dose average values for Total Pharyngeal Residue (i.e., the amount of solid food or liquid material remaining in the pharynx after the first swallow) remained meaningfully reduced at the 180-day post-dose assessment following the administration of the low dose of gene therapy BB-301 as compared to the pre-dose average values recorded for Subject 1 during the OPMD Natural History Study- -Critically, for three of the four food types evaluated during the radiographic swallowing study assessments for Subject 1, the post-dose average Total Pharyngeal Residue values were lower at the 180-day post-dose assessments than at any point during the 9-month pre-dose observation period compr
HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl
-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April- -The Second OPMD Subject was Safely Dosed with BB-301 in February- -Additional Interim Clinical Safety Data and Clinical Efficacy Data are Expected for Several Study Subjects in the Second Half of 2024- -23 OPMD Subjects have Enrolled into the OPMD Natural History Study with Multiple Subjects Eligible for Entry into the BB-301 Phase 1b/2a Clinical Treatment Study- -Closed an Oversubscribed Private Placement Financing of $40.0 Million on April 22nd, Cash Runway Extended Through 2025- HAYWARD, Calif., May 1
HAYWARD, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced that members of Benitec management will participate in Citizens JMP Life Science Conference, taking place in New York, NY from May 13-14, 2024. Presentation Details:Date: May 13, 2024Time: 11:00 am EDTPresenter: Jerel Banks, MD, PhD, Executive Chairman and Chief Executive Officer The Benitec presentation will also be available via live webcast here. Please contact
-First efficacy signals demonstrated for a gene therapy under development for Oculopharyngeal Muscular Dystrophy (OPMD) which affects ~15,000 patients worldwide- - BB-301 facilitated improvements across multiple measures of swallowing function in the first Phase 1b/2a clinical study subject as compared to pretreatment assessments conducted during the observational natural history portion of the study- -Virtual R&D Day being held today at 9:00 am EDT, details below- HAYWARD, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its
HAYWARD, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced a $40.0 million private investment in public equity (PIPE) financing from the sale of 5,749,152 shares of its common stock at a price per share of $4.80, and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 2,584,239 shares of its common stock at a price per pre-funded warrant of $4.7999, to certain institutional accredited i
HAYWARD, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced it will host a virtual R&D Day, on Thursday, April 18, 2024 from 9:00 AM to 11:00 AM ET. To register, click here. The event will feature two key opinion leaders who will discuss the clinical symptoms and the natural history of oculopharyngeal muscular dystrophy (OPMD), a rare genetic muscle disorder. The key opinion leaders will also review the clinical and radiogr
-First Subject Dosed with BB-301 in Phase 1b/2a Clinical Treatment Study (NCT06185673) in November 2023- -Data Safety Monitoring Board Review for First Subject Completed After Day 28 Study Visit- -Second Subject Scheduled to Receive BB-301 in February 2024- -23 Subjects Enrolled into the Oculopharyngeal Muscular Dystrophy Natural History Study with Multiple Subjects Eligible for entry into the Phase 1b/2a Clinical Treatment Study in 2024- HAYWARD, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Re
HAYWARD, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or the "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announced the first subject has been dosed in the BB-301 Phase 1b/2a Clinical Treatment Study. BB-301 is the Company's first gene therapy candidate employing the Silence and Replace approach and is being developed for the treatment of Oculopharyngeal Muscular Dystrophy-related Dysphagia. Dosing of the first subject marks the beginning of the 52-week follow-up period designe
HAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced that Jerel A. Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec, will participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference on Thursday, November 30th, 2023 at 10:00 am ET. A live webcast of the presentation will be accessible from the Investor section of Benitec's website at ir.benitec.com. An archived version of the webcast will b
HAYWARD, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ:BNTC) ("Benitec" or "Company"), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary "Silence and Replace" DNA-directed RNA interference ("ddRNAi") platform, today announces the appointment of Kishen Mehta to the board of directors (BOD) of the Company, effective June 26, 2024. Mr. Mehta's appointment follows the $40.0 million private investment in public equity (PIPE) financing announced on April 18th, led by long-term investor Suvretta Capital, where he serves as portfolio manager. "We are pleased to welcome Kishen to the board as we pl
SC 13D - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13G - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13G - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13G - Benitec Biopharma Inc. (0001808898) (Subject)
SC 13G - Benitec Biopharma Inc. (0001808898) (Subject)
Leerink Partners analyst Mani Foroohar initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $13.
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Overweight rating and announces Price Target of $30.
Gainers CareCloud (NASDAQ:CCLD) stock moved upwards by 80.5% to $2.27 during Monday's regular session. The company's market cap stands at $36.6 million. Novavax (NASDAQ:NVAX) stock rose 42.17% to $12.62. The market value of their outstanding shares is at $1.7 billion. The company's, Q1 earnings came out yesterday. Macrogenics (NASDAQ:MGNX) stock rose 27.79% to $4.23. The market value of their outstanding shares is at $264.6 million. As per the news, the Q1 earnings report came out 2 days ago. Chromocell Therapeutics (AMEX:CHRO) shares moved upwards by 25.68% to $2.3. The market value of their outstanding shares is at $13.5 million. Omega Therapeutics (NASDAQ:OMGA) shares moved upwards b
Revenue $0 Down From
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(1.64) per share which missed the analyst consensus estimate of $(0.78) by 110.26 percent.
- SEC Filing
JMP Securities analyst Silvan Tuerkcan maintains Benitec Biopharma (NASDAQ:BNTC) with a Market Outperform and raises the price target from $10 to $16.
Gainers Bio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. The company's market cap stands at $3.4 million. Biora Therapeutics (NASDAQ:BIOR) shares moved upwards by 8.4% to $0.65. The market value of their outstanding shares is at $23.2 million. Mustang Bio (NASDAQ:MBIO) shares rose 7.78% to $0.4. The market value of their outstanding shares is at $4.1 million. BIMI Intl Medical (NASDAQ:BIMI) shares moved upwards by 7.46% to $1.44. The market value of their outstanding shares is at $20.1 million. Allarity Therapeutics (NASDAQ:ALLR) stock increased by 7.14% to $1.65. The company's market cap stands at $3.2 million. China SXT Pharmac
Thursday, Benitec Biopharma Inc (NASDAQ:BNTC) released interim clinical data from the 90-day timepoint following the administration of BB-301 to the study’s first subject (Subject 1) treated in the BB-301 Phase 1b/2a study in Oculopharyngeal Muscular Dystrophy (OPMD). “To date, no clinical studies have systematically demonstrated a clinical improvement in OPMD patients across both objective and subjective measures of swallowing. We are, therefore, pleased to report positive interim clinical data from multiple radiographic measures as well as subject-reported outcome measures from the first subject treated with BB-301,” said Jerel Banks, Executive Chairman and Chief Executive Officer of Be
3 - Benitec Biopharma Inc. (0001808898) (Issuer)
3 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
4 - Benitec Biopharma Inc. (0001808898) (Issuer)
Guggenheim initiated coverage of Benitec Biopharma with a rating of Buy and set a new price target of $17.00
Leerink Partners initiated coverage of Benitec Biopharma with a rating of Outperform and set a new price target of $13.00
Piper Sandler initiated coverage of Benitec Biopharma with a rating of Overweight and set a new price target of $30.00
HC Wainwright & Co. initiated coverage of Benitec Biopharma with a rating of Buy and set a new price target of $10.00
DEF 14A - Benitec Biopharma Inc. (0001808898) (Filer)
PRE 14A - Benitec Biopharma Inc. (0001808898) (Filer)
8-K - Benitec Biopharma Inc. (0001808898) (Filer)
8-K - Benitec Biopharma Inc. (0001808898) (Filer)
424B3 - Benitec Biopharma Inc. (0001808898) (Filer)
EFFECT - Benitec Biopharma Inc. (0001808898) (Filer)
S-1 - Benitec Biopharma Inc. (0001808898) (Filer)
8-K - Benitec Biopharma Inc. (0001808898) (Filer)
10-Q - Benitec Biopharma Inc. (0001808898) (Filer)
D - Benitec Biopharma Inc. (0001808898) (Filer)